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background: This 11th European IVF-monitoring report presents the results of assisted reproductive technology (ART) treatments
initiated in Europe during 2007.
methods: From 33 countries, 1029 clinics reported 493 184 treatment cycles: IVF (120 761), ICSI (256 642), frozen embryo replacement
(91 145), egg donation (15 731), preimplantation genetic diagnosis/preimplantation genetic screening (4638), in vitro maturation (660) and
frozen oocytes replacements (3607). Overall, this represents a 7.6% increase since 2006, mostly related to an increase in all registers.
IUI using husband/partner’s (IUI-H) and donor (IUI-D) semen was reported from 23 countries: 142 609 IUI-H (+6.2%) and 26 088 IUI-
D( +7.2%).
results: In 18 countries where all clinics reported, 376971 ART cycles were performed in a population of 425.6 million (886 cycles per
million). The clinical pregnancy rates per aspiration and per transfer were 29.1 and 32.8% for IVF, and 28.6 and 33.0% for ICSI. Delivery rate
after IUI-H was 10.2% in women aged , 40 years. In IVF/ICSI cycles, 1, 2, 3 and ≥4 embryos were transferred in 21.4, 53.4, 22.7 and 2.5%
of cycles, with no decline in the number of embryos per transfer since 2006. The proportion of multiple deliveries (22.3: 21.3% twin and 1.0%
triplet), did not decrease compared with 2006 (20.8%) and 2005 (21.8%). In women , 40 years undergoing IUI-H, twin deliveries occurred
in 11.7% and triplets in 0.5%.
conclusions: In comparison with previous years, the reported number of ART cycles in Europe increased in 2007; pregnancy rates
increased marginally, but the earlier decline in the number of embryos transferred and multiple births did not continue.
Key words: European Society of Human Reproduction and Embryology / assisted reproduction technology / intrauterine insemination /
register data
Introduction
This report is the 11th annual European Society of Human Reproduc-
tion and Embryology (ESHRE) publication on European data on
assisted reproductive technology (ART). The 10 previous reports,
also published in Human Reproduction (ESHRE, 2001a,b, 2002,
2004, 2005, 2006, 2007, 2008; Nyboe Andersen et al., 2009; de
Mouzon et al., 2010), covered treatment cycles from 1997 to 2006.
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Nygren (special advisor). V. Goossens is Science Manager at ESHRE Central Ofﬁce, Brussels. See also Appendix for contributing centres and contact persons representing the data collection
programmes in the participating European countries. ESHRE pages content is not externally peer-reviewed. The manuscript has been approved by the Executive Committee of ESHRE.
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Advanced Access publication on February 17, 2012 doi:10.1093/humrep/des023As in the last report, the printed version contains the four most im-
portant tables. Additional tables are available online, making the
whole report consistent with those from previous years. In the pub-
lished report, these tables will be referred as ‘Supplementary data,
Tables SI–SXVIII’. The main results of this report were presented at
the annual ESHRE congress in Rome, July 2010.
Materials and Methods
Data collection
Data on ART have been collected from 33 European countries, covering
IVF, ICSI, frozen embryo replacement (FER), egg donation (ED), in vitro
maturation (IVM), pooled data on preimplantation genetic diagnosis
(PGD) and preimplantation genetic screening (PGS) and frozen oocyte
replacements (FOR). In addition to ART, data on intrauterine insemina-
tions using husband/partner’s semen (IUI-H; 22 countries, 2 more than
in 2006) and donor semen (IUI-D; 18 countries, as in 2006) were also
included. The report includes treatments started between the 1 January
and the 31 December 2007. Follow-up data on pregnancies and deliveries
are cohort data, based on the reported cycles.
The forms were the same as in 2006, making all tables comparable. As in
previous years, data were directly entered in ESHRE’s computer system by
each country co-ordinator, through software developed by ESHRE. Data
analysis was performed in ESHRE headquarters by V. Goossens.
Results
Participation
The present report includes data from an additional country (Bosnia)
(Table I). The proportion of reporting clinics (86%, 1029 out of 1204
clinics, listed in Supplementary data) was the same as in 2006. In 18
countries, the coverage, as in 2006, reached 100%. Two countries
(Ireland and Switzerland) were able to report data from all but a
single Centre, but participation was limited (25–50%) in six others
(Bosnia, Bulgaria, Hungary, Lithuania, Poland and Serbia) and very
low (≤25% of clinics) in Greece and Latvia.
Number of treatment cycles
In total, 493 184 cycles were reported, 34 425 more than in 2006
(+7.5%). Among the 377403 fresh cycles (+7.8%), 120761 were
IVF (+2.9%) and 256642 ICSI (+10.3%). The proportion of ICSI
thus reached 68.0% of ‘fresh’ ART cycles (66.5% in 2006). The pro-
portion of FER cycles compared with ‘fresh’ cycles was 24.2%—a
ﬁgure comparable to the ﬁgure of 2006 (24.6%). The number of ED
cycles, reported by 22 countries, increased more than that observed
in fresh IVF/ICSI cycles, reaching 15 731 (+24.4%), the main contribu-
tor being Spain (7985 cycles, +22%). PGD was reported by 14 coun-
tries, with fewer cycles (4638, 229.3%) recorded in 2007. The main
reason was absence of data from Turkey, who contributed 2308
cycles in 2006. Higher rates of IVM were reported (660, +267% com-
pared with 2006). Finally, 3607 FOR cycles were reported (+1.0%),
the majority from Italy (n ¼ 2994). Table I also shows the number
of cycles per million women of reproductive age (15–45 years) and
per million inhabitants, in the 18 countries where data coverage was
100%. The highest availability of ART cycles was reported from
Nordic countries, particularly in Denmark (14067 and 2558),
followed by Belgium, Finland, Iceland, Sweden, Norway and Slovenia,
all of which provided over 8000 per million women aged 15–45 years
and 1700 cycles per million inhabitants, respectively. More details are
reported in Supplementary data, Table SI.
Reporting methods and size of the clinics
Among the 18 countries with complete reporting (Supplementary
data, Table SII), the register was compulsory for 14 [10 held by a Na-
tional Health Authority (NHA) 3 by a medical organization (MO) and
1 by personal initiative] and voluntary for 4 (three held by a MO and
one by a NHA). Only seven registers were based on individual forms,
i.e. cycle by cycle.
Among the 15 countries with partial coverage, 6 were held by an
NHA/NGO and 3 were based on individual forms.
The distribution of clinics according to the number of cycles varied
considerably among the countries (Supplementary data, Table SIII).
For example, in Italy 44.1% of the clinics provided fewer than 100
cycles annually, whereas in Belgium and in the Netherlands 61% of
the clinics performed more than 1000 cycles a year.
Pregnancies and deliveries after treatment
Table II shows pregnancy and delivery rates per aspiration for IVF, ICSI
and FER. Three countries provided outcome only per embryo trans-
fer, while three did not provide data on deliveries. Thus the mean
pregnancy rate and delivery rate were computed for countries provid-
ing the relevant information. There were huge variations across the
countries. On average, pregnancy rates were 29.1% (+0.1% com-
pared with 2006) and 28.6% (21.3%) per aspiration for IVF and
ICSI, and 20.1% per thawing for FER (+1.0%). Mean delivery rates
per aspiration (per thawing for FER) were 21.1, 20.2 and 13.5%, re-
spectively (20.4, +1.8 and +0.8%). The detailed numbers of
cycles, aspirations, transfers, pregnancies, deliveries and the corre-
sponding rates per technique are reported in Supplementary data,
Table SIV for IVF, Supplementary data, Table SV for ICSI and Supple-
mentary data, Table SVI for FER.
In total, 96 690 babies were recorded as having been born in the 29
countries where the reporting from IVF, ICSI and FER included new-
borns (+8185). In countries with complete reporting, the percentage
of babies conceived through ART varied from 0.5% of the national
births in Turkey to 4.9% in Denmark. More details are provided in
Supplementary data, Table SI, showing that the percentage of ART
babies was above 3.0% in most of the Nordic countries, whereas
this percentage was between 1.2 and 1.8% in the largest European
countries (Germany, France, UK and Italy).
ED was reported by 22 countries (Supplementary data, Table SVII).
In total, 6628 clinical pregnancies (+1112) resulted from 14334
embryo transfers (+1649), with pregnancy rates of 46.2% per transfer
versus 43.5% in 2006. The mean delivery rate was 30.8% per transfer
(n ¼ 4448) in the 21 countries reporting deliveries.
Age distribution
The age distribution of women treated with IVF varied across coun-
tries (Supplementary data, Table SVIII). In four countries, more than
20% of women were aged 40 years or more (Greece, Ireland, Italy
and Switzerland), whereas it was ,5% in Albania, Poland and Slo-
venia. As expected, pregnancy rates decreased with age, from
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Table I ART in European countries in 2007.
IVF clinics in the
country
Treatment cycles Cycles/million*
Total Reporting IVF ICSI FER ED IVM PGD FOR All Women 15–45 years of age Population
Albania 3 1 66 79 16 161
Austria 26 26 1172 4050 306 0 5528 3252 674
Belgium 18 18 3852 12357 7499 751 24459 12230 2352
Bosnia 5 2 31 131 0 162
Bulgaria 15 7 574 708 79 8 0 0 0 1369
Cyprus 7 5 482 823 155 112 2 16 1590
Czech Republic 24 24 1947 7225 4169 1221 498 15060 6845 1476
Denmark 23 23 6054 4981 2668 140 111 113 14067 14067 2558
Finland 18 18 2931 1793 3529 314 23 25 320 8935 11169 1718
France 104 104 20211 31635 14772 742 88 124 67572 5363 1061
Germany 118 118 11811 33371 17140 62322 3944 756
Greece 38 9 829 1360 193 92 5 9 15 2503
Hungary 10 5 594 1843 620 48 0 6 17 3128
Iceland 1 1 215 174 244 32 0 0 0 665 11083 2217
Ireland 7 6 1768 1096 692 9 0 0 3565
Italy 202 202 8792 31213 709 2994 43708 3834 751
Latvia 4 1 104 75 113 60 0 0 352
Lithuania 4 2 181 198 46 425
Macedonia 3 3 504 475 29 1008 2520 504
Montenegro 2 2 25 253 278 2780 397
Norway 11 11 2805 2794 2250 0 22 0 0 7871 8746 1711
Poland 38 17 237 4639 2238 347 51 0 3 7515
Portugal 22 22 1536 2960 524 101 0 115 0 5236 2380 494
Russia 69 55 12568 9269 3084 1367 299 382 14 26983
Serbia 12 6 670 450 6 1126
Slovenia 3 3 885 1997 521 7 0 16 2 3428 8570 1714
Spain 182 111 3476 31023 9089 7985 28 2785 234 54620
Sweden 16 16 5423 4768 4500 281 6 83 15061 8859 1673
Switzerland 26 25 1038 3465 3312 0 0 0 0 7815
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.34.0% through 26.5–13.9% for women aged ≤34, 35–39 years and
≥40 years, respectively, and the same trend was seen for delivery
rates (26.2, 19.5 and 9.2%, respectively). Similar ﬁndings were found
for ICSI (Supplementary data, Table SIX). For FER (Supplementary
data, Table SX), only 12.6% of women were aged 40 years or more
at transfer. In ED (Supplementary data, Table SXI), the recipient was
aged 40 years or more in 55.3% of cases on average, and only a few
countries had a proportion lower than 50%: Albania (37.5%), Belgium
(41.3%), Denmark (35.0%), Hungary (31.6%), Serbia (33.3%), Sweden
(9.2%) and Ukraine (44.1%). Pregnancy and delivery rates in oocyte
recipients were comparable across different age groups.
Number of embryos transferred and multiple
deliveries
Table III shows the number of embryos transferred after IVF and ICSI
combined. The total percentage of single embryo transfers (SETs)
was 21.4% (22.1% in 2006), double embryo transfers (DETs) 53.4%
(57.3% in 2006), triple embryo transfers 22.7% (19.0% in 2006) and
four or more embryo transfers 2.5% (1.6% in 2006). Information
about numbers of elective single transfers is not yet available. As indi-
cated in this table, major differences were seen between countries. In
2007, several countries reported a high number of SETs. The highest
levels were found in Sweden (69.9%), Finland (57.8%) and Belgium
(50.2%). The proportion of triple embryo transfers ranged from zero
in Sweden to 58.6% in Greece. Transfer of four or more embryos
ranged from zero in 10 countries and ,1% in 3 to 18.3% in Macedonia.
In fresh cycles, the percentages of multiple deliveries were 21.3%
for twins (19.9% in 2006) and 1.0% for triplets (0.9% in 2006).
After FER, the percentages were 13.1% for twin deliveries (13.4% in
2006) and 0.3% for triplets (0.4% in 2006). Additional data on preg-
nancy outcome, singleton and multiple deliveries are provided in Sup-
plementary data, Table SXII (for fresh cycles) and Supplementary data,
Table SXIII for FER.
Risks and fetal reductions
Supplementary data, Table SXIV shows the risk of preterm deliveries
according to the number of newborn. Data were available from 15
countries. It shows that the risk of extreme preterm birth (gestational
Week 20–27) increases from 1.0% for a singleton delivery, to 3.2%
for twins and 11.8% for triplets. The same trend was noted for very
preterm (28–32 weeks), from 2.7 to 11.1 and 35.7%, respectively,
and for preterm (33–36 weeks), from 9.2 to 38.3 and 44.5%,
respectively.
Ovarian hyperstimulation syndrome (OHSS) was reported in 26 of
the 33 countries (Supplementary data, Table SXV). In total, 2470
cases of OHSS were recorded, corresponding to a risk of OHSS of
0.7% in those countries (0.8% in 2006) of all stimulated cycles. Supple-
mentary data, Table SXV also includes other adverse outcomes, such
as fetal reductions (n ¼ 364).
Preimplantation genetic diagnosis/
preimplantation genetic screening
PGD/PGS activity was recorded from 14 countries (Table I) and
involved 4638 cycles, 4274 aspirations, 2882 embryo transfers and
706 deliveries (16.5% per aspiration), the main contributors being
Spain (2785 cycles).
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Table II Results after ART in 2007.
Country Cycles
IVF 1 ICSI
IVF ICSI FER ART
infants
a
ART
infants
per
national
births
(%)
Aspirations Pregnancies
per
aspiration
(%)
Deliveries
per
aspiration
(%)
Aspirations Pregnancies
per
aspiration
(%)
Deliveries
per
aspiration
(%)
Thawings
FER
Pregnancies
per thawing
(%)
Deliveries
per
thawing
(%)
Albania 145 65 40.0 33.8 78 37.2 29.5 64
Austria 5222 306 30.7
Belgium 3852 29.8 22.4 12357 28.4 20.6 7499 15.3 11.3 4925 4.1
Bosnia 162 28 32.1 14.3 114 19.3 12.3 19
Bulgaria 1282 532 33.8 25.6 675 31.6 25.8 79 15.2 8.9 378
Cyprus 1305 457 39.2 792 40.2 0.0 155 23.9
Czech Republic 4169 23.5 15.9
Denmark 11035 5819 26.1 21.3 4952 26.0 21.3 2668 16.5 13.5 3156 4.9
Finland 4724 2830 27.3 20.6 1759 27.9 22.4 3475 21.2 16.0 1875 3.2
France 20211 24.6 19.2 31635 25.9 20.5 14710 1.8
Germany 45182 10995 29.4 16.0 32124 28.2 16.1 17140 18.3 9.9 10483 1.5
Greece 2189 780 36.8 26.5 1295 32.8 24.2 193 22.8 14.0 764
Hungary 2437 544 27.4 21.5 1787 28.2 22.8 620 23.1 13.2 776
Iceland 215 25.1 21.9 174 28.2 23.0 168 3.7
Ireland 2864 1466 33.9 27.4 974 29.0 26.3 692 22.4 15.5 958
Italy 40005 7570 22.0 15.2 28075 22.0 14.3 709 14.7 8.3 6575 1.2
Latvia 179 104 42.3 75 29.3 113 7.1 20
Lithuania
Macedonia 979 491 30.3 24.2 461 29.1 21.0 29 31.0 20.7 287 1.2
Montenegro 278 24 20.8 20.8 246 22.8 20.3 66 0.8
Norway 5599 2685 30.2 26.1 2703 27.3 23.2 2250 19.7 16.0 1509
Poland 4876 220 33.2 28.2 4547 35.4 29.0 2238 20.9 16.0 2164
Portugal 4496 1329 30.6 23.7 2692 27.9 20.4 524 16.4 11.8 1186 1.2
Russia 21837 12171 35.2 24.1 9002 33.1 20.4 3084 23.9 14.9 7197
Serbia 1120 648 24.5 17.3 426 34.5 29.8 277
Slovenia 2882 844 33.9 25.7 1932 28.5 23.7 521 18.8 14.2 913 4.6
Spain 34499 3041 34.6 27905 33.6 9089 23.1 12647
Sweden 10191 5011 32.0 24.7 4500 28.4 22.4 4500 23.2 17.2 3260 3.1
Switzerland 4503 886 28.1 20.9 3235 27.4 20.1 3312 18.7 12.6 1467
The Netherlands 16163 8399 27.6 20.5 6659 31.8 25.1 4616 2.5
Turkey 785 34601 5262 0.5
Ukraine 3946 1790 40.3 29.8 2028 37.4 30.9 579 29.2 22.8 1812
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.In vitro maturation
IVM was recorded in 11 countries, three more than in 2006 (Table I).
A total of 660 aspirations (241 in 2006) were recorded, resulting in 74
pregnancies and 44 deliveries (6.7% per aspiration).
Intra-uterine inseminations
Table IV provides data on IUI-H and IUI-D, reported by 23 countries
(one more than in 2006), with 1 country reporting only donor insem-
ination (Sweden), whereas 5 countries did not report/practice IUI-D
(Albania, Bosnia, Italy, Lithuania and Serbia).
For non-donor insemination (IUI-H), 142 609 cycles were reported
(+8348), the main contributors being France, Italy and Spain. Among
the countries reporting deliveries, the mean delivery rate was 9.2% per
cycle (+0.7), 11.4% of deliveries being twin (+0.8%) and 0.6% triplet
deliveries (20.2%).
For donor insemination (IUI-D), 26 088 cycles were reported
(+1749), the main contributors being Denmark, Spain and France.
The delivery rate was 13.8% per cycle (+1.4%), with multiple delivery
rates similar to IUI-H.
Data were also divided in two female age groups, below 40 years
(upper panel) and 40 years or more (lower panel), both for IUI-H
(Supplementary data, Table SXVI) and IUI-D (Supplementary data,
Table SXVII). For France, stratiﬁcation for age was not possible. The
delivery rate associated with IUI-H declined with age (10.2% below
40 years versus 6.3% above), and the multiple delivery rate decreased
slightly from 11.7 to 9.9% for twins, and from 0.5 to 0.0% for triplets.
Similar ﬁndings were seen in IUI-D, where delivery rates decreased
from 14.6 to 6.1%, twin deliveries from 10.2 to 6.5%, and triplets
from 0.5 to 0.0%.
Cumulative delivery rates
Supplementary data, Table SXVIII gives an estimation of the cumula-
tive delivery rates per initiated fresh stimulated cycle. This is not the
true cumulative delivery rate per couple per cycle but shows the
number of deliveries obtained from the FER cycles added to the deliv-
eries from the stimulated cycles during the same year. Additionally, the
table shows the rate of multiple deliveries after the ‘fresh’ cycles and
the FER combined. It shows that adding the deliveries after FER
increases the delivery substantially (Finland +11.8%, Iceland
+12.8%, Sweden +7.7% and Switzerland +9.2%). The overall mul-
tiple delivery rate was particularly low in Sweden and Finland: 5.3
and 10.9%, respectively, with relatively high cumulative DR (29.7
and 32.5%).
Discussion
The present report is the 11th consecutive, annual European report
on ART data. Together, these reports cover treatment cycles from
1997 to 2007. It can be argued that as long as data are incomplete,
lack uniformity in terms of clinical deﬁnitions and are generated
through different methods of data collection, they should be inter-
preted carefully, and the focus should primarily be on speciﬁc
country data. Nevertheless, summary data reveal important trends
in practice and outcomes.
As seen in the tables, registers from a number of countries have
been unable to provide some of the data. In order to standardize
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Table III Number of embryos transferred and deliveries after ART in 2007.
Country IVF 1 ICSI FER
Transfers 1 embryo (%) 2 embryos (%) 3 embryos (% ) 4 1 embryos (%) Deliveries Twin (%) Triplet (%) Deliveries Twin (%) Triplet (%)
Albania 131 25.2 29.0 44.3 1.5 45 17.8 2.2
Austria 4912 20.3 68.7 9.8 1.2
Belgium 14876 50.2 39.6 8.4 1.7 3386 11.8 0.3 845 13.1 0.1
Bosnia 123 49.6 13.8 25.2 11.4 18 5.6 0.0
Bulgaria 1126 8.3 35.6 44.2 11.9 310 14.8 1.6 7 14.3 0.0
Cyprus
Czech Republic 2711 662
Denmark 9226 39.6 55.7 4.5 0.1 2298 16.6 0.1 361 14.1 0.0
Finland 4131 57.8 41.9 0.3 0.0 977 11.3 0.2 560 9.6 0.2
France 44453 23.2 62.3 13.2 1.3 10 359 18.9 0.4 1913 11.3 0.2
Germany 41615 12.5 66.9 20.6 0.0 6950 21.2 0.6 1702 15.1 0.6
Greece 1852 11.9 19.3 58.6 10.3 521 25.7 0.8 27 3.7 0.0
Hungary 2146 10.1 45.3 35.7 8.9 524 22.5 2.1 82 18.3 0.0
Iceland 322 46.6 46.0 7.5 0.0 87 17.2 0.0 50 12.0 0.0
Ireland 2221 13.6 77.4 9.0 0.0 658 24.3 0.9 107 17.8 0.0
Italy 30780 20.4 30.5 49.1 0.0 5158 20.6 2.8 59 6.8 1.7
Latvia 173 15.0 53.8 31.2 0.0
Lithuania
Macedonia 750 23.9 26.9 30.9 18.3 216 26.4 1.4 6 33.3 0.0
Montenegro 258 14.3 32.2 41.1 12.4 55 16.4 1.8
Norway 4821 1324 13.4 0.3 361
Poland 4338 16.6 67.9 15.1 0.4 1382 20.3 0.6 359 12.8 0.0
Portugal 3585 17.4 69.2 13.3 0.2 863 21.6 0.9 62 17.7 0.0
Russia 19510 16.2 59.6 19.8 4.4 4526 26.0 1.5 460 17.2 1.7
Serbia 911 13.3 77.1 6.9 2.7 239 8.8 3.3
Slovenia 2462 27.6 69.7 2.6 0.0 674 23.0 0.0 74 6.8 0.0
Spain 27155 5990 27.1 0.7 1092 17.3 0.4
Sweden 8529 69.9 30.1 0.0 0.0 2246 4.6 0.1 776 6.7 0.1
Switzerland 3731 12.8 65.3 21.9 0.0 830 18.9 0.5 417 12.0 0.7
The Netherlands 13375 3396 15.1 0.1 629 11.0 0.0
Turkey 31808 11.5 24.1 52.8 11.7 3727 32.9 4.1
Ukraine 3510 11.3 44.2 33.1 11.4 1160 25.0 1.6 132 22.7 0.0
United Kingdom 31114 12.8 82.3 4.9 0.0 9094 24.1 0.3 1548 17.6 0.3
All* 263 681 21.4 53.4 22.7 2.5 63617 21.3 1.0 11212 13.1 0.3
*Totals refer only to these countries where data on number of transferred embryos and on multiplicity were reported. Transfers: data on transfers not available for Austria, Cyprus, Czech Republic, Lithuania, Norway, Spain and The
Netherlands. Belgium: 6 more cycles without data (not included), Russia: 1878 more cycles without data (not included), Switzerland: 1 more cycle without data (not included). FER: for 1 delivery multiplicity is not known. Belgium, IVF + ICSI:
for 21 deliveries, multiplicity is not known, FER: for 8 deliveries multiplicity is not known. Russia, IVF + ICSI: for 243 deliveries multiplicity is not known, FER: for 47 deliveries multiplicity is not known. Turkey: underestimation of the deliveries,
no data for FER.
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Table IV Intrauterine insemination with husband (IUI-H) or donor (IUI-D) semen in 2007.
Country IUI-H IUI-D
Cycles Deliveries Deliveries (%) Singleton (%) Twin (%) Triplet (%) Cycles Deliveries Deliveries (%) Singleton (%) Twin (%) Triplet (%)
Albania 36 4 11.1 100.0 0.0 0.0 0
Austria
Belgium
Bosnia 108 21 19.4 85.7 9.5 4.8
Bulgaria 846 72 8.5 90.3 9.7 0.0 211 32 15.2 90.6 9.4 0.0
Cyprus
Czech Republic
Denmark 9176 1112 12.1 86.1 13.8 0.2 6254 749 12.0 90.0 9.9 0.1
Finland 3782 318 8.4 93.7 6.0 0.3 822 112 13.6 93.8 6.3 0.0
France 49240 4923 10.0 88.1 11.4 0.5 4307 661 15.3 86.4 13.0 0.6
Germany
Greece 936 123 13.1 97.6 2.4 0.0 234 36 15.4 100.0 0.0 0.0
Hungary 2112 203 9.6 82.3 15.8 2.0 176 28 15.9 82.1 17.9 0.0
Iceland
Ireland 1217 138 11.3 90.6 8.7 0.7 170 39 22.9 82.1 10.3 7.7
Italy 31551 2076 6.6 88.2 10.7 1.1
Latvia 36 64
Lithuania 610
Macedonia 773 53 6.9 90.6 9.4 0.0 33 7 21.2 85.7 14.3 0.0
Montenegro
Norway 380 35 9.2 96.9 3.1 0.0 165 26 15.8 84.6 15.4 0.0
Poland 5534 565 10.2 93.6 6.2 0.2 1139 162 14.2 93.8 6.2 0.0
Portugal 1719 152 8.8 88.2 11.8 0.0 236 50 21.2 84.0 14.0 2.0
Russia 3697 465 12.6 89.8 9.8 0.4 1534 233 15.2 88.0 11.1 1.0
Serbia 161 12 7.5 91.7 0.0 8.3
Slovenia 625 41 6.6 92.7 4.9 2.4 8 1 12.5 100.0 0.0 0.0
Spain 22917 2059 9.0 84.8 14.5 0.6 5917 831 14.0 86.6 12.8 0.6
Sweden 492 72 14.6
Switzerland
The Netherlands
Turkey
Ukraine 1365 125 9.2 93.6 5.6 0.8 741 139 18.8 92.8 7.2 0.0
United Kingdom 5788 3585 423 11.8 92.7 6.9 0.5
All
a 142 609 12497 9.2 88.0 11.4 0.6 26 088 3601 13.8 89.0 10.5 0.5
For the UK: the Human Fertilisation and Embryology Authority only started collecting data for IUI-H from 05/07/2007 onwards. The number of IUI-H cycles submitted for the UK (5788) is therefore not for a full year.
Data on deliveries were removed for Lithuania.
aTotal refers to these countries where data were reported and mean percentage were computed for countries with complete information. IUI-H: For Austria, Belgium, Cyprus, Czech Republic, Germany, Iceland, Montenegro, Sweden,
Switzerland, The Netherlands and Turkey, no dataavailable. France: 1187 cycles excluded due to unknown age of women, in 90 deliveries multiplicity is not known. Ireland: one clinic did not provide data. Italy: underestimation of the numberof
deliveries due to lost follow-up. Norway: in three deliveries multiplicity is not known. Russia: For 24 deliveries multiplicity not known. UK: no data on deliveries. IUI-D: For Austria, Belgium, Bosnia, Cyprus, Czech Republic, Germany, Iceland,
Italy, Lithuania, Montenegro, Serbia, Switzerland, The Netherlands and Turkey, no data available. France: for 6 deliveries multiplicity is not known. Russia: For 25 deliveries multiplicity is not known. Sweden: in all 72 deliveries multiplicity is not
known.
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1deﬁnitions and reporting, the ICMART (International Committee for
Monitoring Assisted Reproductive Technologies) glossary has been
published (Zegers-Hochschild et al., 2006a,b), and recently revised
with the World Health Organization (Zegers-Hochschild et al.,
2009a,b). It is likely that these recommendations were not perfectly
implemented in all reporting countries in 2007, meaning that, as in
every registry report, the data must still be interpreted with some
caution.
In 2007, the number of countries reporting to ESHRE’s EIM Con-
sortium increased to 33, covering the whole of Western Europe.
Bosnia joined the consortium from this year but reporting was
patchy in Eastern and South Eastern Europe. No data were available
from Estonia, Romania and Slovakia, and Croatia was unable to
provide data for 2007.
In 2007, the coverage was 86.0% of all clinics—a ﬁgure similar to
2006. However, the coverage was still low in a few countries, such
as Greece (9 of 50 clinics), Poland (17 of 38 clinics) and Spain (111
of 182 clinics). The implementation of new regulations may result in
an improvement in the coming years.
Overall, the number of reported cycles increased by 7.8% since
2006—reaching a total of 493 184. This was due an overall increase
in ART, rather than more intensive coverage, as participation
remained at the same level and only a few cycles were contributed
by the new country that joined the Consortium. The present report
also includes data from almost 169000 IUI cycles—9000 more than
in 2006. Within Europe, the largest numbers of ART cycles were
reported from France (68000), Germany (62 000), Spain (55 000),
the UK (47 000) and Italy (44000). Elsewhere in the world in 2007,
138 198 cycles were reported from the USA (CDC, 2009), and 56
817 cycles from Australia and New Zealand (AIHW, 2009).
Reduction in the re-imbursement for ART had resulted in a sharp
decline in the number of cycles from Germany between 2003 and
2005 (from 102000 to 53 000). There has been a slow but gradual
increase since then up to 62000 cycles. The German example pro-
vides good evidence that a public re-imbursement policy of ART has
a major impact on the number of treatments.
As shown in Table I in countries with a full report, the average
number of treatment cycles per million inhabitants ranged from 397
in Montenegro to 2558 in Denmark. A better way to deﬁne the avail-
ability of ART is to report ART cycles in women of reproductive age
(15–49 years), which eliminates the impact of age differences across
the countries (Table I). Again, there were huge differences, from
1944 cycles per million women in Turkey, to 14 067 in Denmark
(Table I). Finally, the percentage of newborns conceived through
ART varied from 0.5% in Turkey to 4.9% in Denmark (Supplementary
data, Table SI). It is difﬁcult to explain those differences which may be
related to several factors, such as cost, reimbursement, legal or social
aspects, as well as medical strategies relating to the use of ART. These
issues also may play a role in the differences observed in pregnancy
and delivery rates between countries.
A further question relates to the choice of a suitable denominator in
reporting outcomes per cycle. There is general agreement in favour of
reporting the number of deliveries (or clinical pregnancies) per
initiated cycle. However, from Supplementary data, Tables SIV and
SV, it can be noticed that the cancellation rate (average 8.4% for
IVF and 5.9% for ICSI) shows huge variations (from 0 to 17%),
making it difﬁcult to compare outcomes of started cycles. Efforts still
need to be made to better register initiated cycles if we want to
analyse this marker.
The proportion of ICSI versus conventional IVF procedures con-
tinues to increase (49% in 2004, 66.5% in 2006 and 68% in 2007).
A similar trend has been observed in the USA (Jain and Gupta,
2007). As recently reviewed, the trend towards increased use of
ICSI has been observed throughout the world (Nyboe Andersen
et al., 2008; ICMART et al., 2009). In Australia and New Zealand,
61.8% of all cycles used ICSI in 2007 and in the USA the correspond-
ing ﬁgure was 63%, so there is a uniform development in those three
regions. However, within Europe a marked variation exists regarding
the distribution between IVF and ICSI. As can be seen in Table I,1 1
countries used ICSI in more than 75% of cases, the highest being
Turkey (97.8%). In contrast, in the Nordic countries, the Netherlands,
Russia, Ireland, the UK, and a few other countries, IVF remain the
dominant technology. As recently analysed (Nyboe Andersen et al.,
2008), the marked increase in the use of ICSI cannot be explained
by a similar increase in male infertility but rather to a more liberal
use of this technique in cases with mixed caused of infertility,
unexplained infertility, mild male factor infertility and fertilization
failures. Thus, the observed differences can be at least partly
explained by differences in professional strategies and clinical decision
making.
The trend towards the transfer of fewer embryos was no longer
observed in 2007 and cycles where three or more embryos were
transferred increased from 20.6 to 25.2% (Table III). The mean per-
centage of SETs decreased from 22.1% in 2006 to 21.4%, and the pro-
portion of DETs decreased by almost 4% since 2006. However, these
ﬁndings were mostly explained by the inclusion of data from Turkey,
which contributed a large number of treatment cycles. Turkey had
not reported the number of transferred embryos in 2006 but, in
2007, 52.8 and 11.7% of transfers involved three and four or more
embryos. Exclusion of these data reveals the overall percentages of
transfers of 1, 2, 3, and 4 or more embryos to be 22.8, 57.5, 18.5,
and 1.2%, respectively, which are more in keeping with the trend
seen over the last 10 years.
The same explanation can be given for the increase in multiple preg-
nancies (21.3% twins and 1.0% triplets). When recalculating data after
excluding Turkish ART data, the mean percentages were 20.5 and
0.8%. Thus, the remarkable reduction in triplet deliveries observed
previously may persist (3.6% in 1997 to 0.8% in 2007).
There are clearly many differences across the countries. As seen in
Table III, ﬁve countries reported transfer of a SET in more than 45% of
all transfers (one more than in 2006): Sweden (69.9%), Finland
(57.8%), Belgium (50.2%), Bosnia (49.6%) and Iceland (46.6%), all
with an increase from 0.3 to 11.5% since 2006. In contrast, more
than 10% of transfers involved four or more embryos in seven coun-
tries (Bosnia, Bulgaria, Greece, Macedonia, Montenegro, Turkey and
Ukraine), and the transfer of three embryos reached 58% in
Greece, 53% in Turkey and 49% in Italy. This resulted in 4.1 and
32.9% triplet and twin deliveries in Turkey.
In comparison with the situation in Europe, data from other regis-
ters show that SET was performed in 63.7% of cycles in Australia
and New Zealand (AIHW, 2009), and in 9.4 and 13.1% of transfers
at Day 3 and 5, respectively, in the USA (CDC, 2009).
This report is unable to discriminate between elective SET (eSET)
versus SET in general but the rise in the number of transfers of one
962 de Mouzon et al.embryo is undoubtedly related to a rise in eSET and not a rise of
cycles with only one embryo obtained.
As evident from Table III, major differences in triplet rates are still
evident across countries. We have included data describing preterm
birth rates according to the number of fetuses of the pregnancy (Sup-
plementary data, Table SXIV), which was provided by 15 countries.
The risk of extreme preterm birth (,28 weeks) was increased
3-fold for twins and by almost twelve fold for triplets. The risk of
very preterm (28–32 weeks) birth was increased almost four for
twins and 13-fold for triplets.
Fetal reductions are always performed in triplet or higher order
gestations. Thus, when analysing the range of triplet delivery rates in
different countries, the number of fetal reductions should also be con-
sidered. A total of 364 procedures were reported (82 fewer than in
2006). However, the total number is likely to be an underestimate
since several countries, including large countries such as France,
Germany and the UK, did not report fetal reductions in 2007.
Without this intervention, the proportion of triplet deliveries would
have been much higher than the number of recorded triplet deliveries
(615 in total), given that a number of countries did not report on fetal
reductions.
Finally, delivery rates per aspiration showed a marginal increase for
IVF (21.9%) and ICSI (19.9%) compared with ﬁgures from 2006 (21.5
and 18.4%), as did the delivery rate per thawing for FER (13.5% in
2007 versus 12.7% in 2006).
The delivery rates in Europe remain lower than in the USA where
33.3 and 32.5% of aspirations for IVF and ICSI, respectively, from non-
donor cycles resulted in a delivery (CDC, 2009).
However, the delivery rates in Europe are very similar to those
achieved in Australia and New Zealand, where the delivery rate per
transfer was 23.9% after fresh cycles and 16.0% after FER transfers
in 2007 (AIHW, 2009).
The effect of women’s age on treatment outcome has been
reported since 2006. In 2007, the pregnancy rates per initiated IVF
cycle decreased from 34.0% in women aged less than 35 years, to
13.9% in those aged 40 years or more (Supplementary data, Table
SVIII). Similar trends were noted for ICSI (from 33.3 to 12.2%, Supple-
mentary data, Table SIX) and FER (from 21.7 to 14.4%, Supplemen-
tary data, Tables SX), but not for ED (Supplementary data, Table
SXI). These supplementary tables also provide delivery rates per
cycle. It is important to consider these tables since they better
allow comparing the countries, as age is a major prognostic factor
that is unequally distributed across the countries.
With the noticeable decline in the number of embryos transferred,
the cumulative delivery rate per started cycle may be a most relevant
end-point for ART (Supplementary data, Table SXVIII). In fact, the
present method of calculation of this cumulative delivery rates is meth-
odologically ﬂawed because it represents the sum of fresh and FER
pregnancies obtained in the same calendar year, rather than the FER
pregnancies accruing from a single oocyte aspiration procedure. It
should, however, be stressed that the precise ﬁgure, which can only
be obtained a few years after the initial oocyte aspiration, is likely to
be rather similar to our estimate. In several countries, the addition
of FER deliveries contributed a substantial increase to the delivery
rates per cycle: Finland (20.7–32.5%), Iceland (22.4–35.2%),
Sweden (22.0–29.7%) and Switzerland (18.6–27.8%), justifying their
transfer and freezing policies.
PGD/PGS activity was recorded from 14 countries, and included
4638 cycles resulting in 706 deliveries (15.2% per aspiration). Detailed
analysis of PGD/PGS in Europe will be published separately by
ESHRE’s PGD Consortium (Sermon et al., 2007).
The major differences between countries in terms of the provision
of certain techniques, such as ED and PGD, must be viewed as
markers of cross-border reproductive care where couples who do
not have access to ART in their home countries, travel elsewhere
for treatment. This phenomenon raises important public health con-
cerns and underlines the need for more information in order to facili-
tate a detailed evaluation. This will be addressed by EIM in the coming
year.
Regarding direct risks of ART, OHSS was recorded in 0.7% of
cycles, at the same level as in 2006 (0.8%). However, there may be
a degree of under-reporting, since the rate varies between 0.3 and
13% in the countries reporting OHSS.
For the sixth consecutive year, the present report includes Euro-
pean data on treatments with IUI-H (143 000 cycles) and IUI-D (26
000 cycles), thus showing an increase in IUI-H (+8000) and in
IUI-D (+2000), compared with 2006. The coverage of IUI activities
by the national registers is less comprehensive than for the in vitro
techniques. In women below 40 years of age the delivery rate was
10.2% for IUI-H and 14.6% for IUI-D.
After IUI (both partner and donor insemination), twin pregnancies
were observed in approximately half as many cases when compared
with IVF/ICSI but triplet rates were comparable.
In summary, the present 11th ESHRE report on ART for Europe in
2007 shows a continuing expansion of numbers of participating clinics,
countries and treatment cycles reported. The rise in the use of ICSI
continued and reached 68.0% in 2007. Delivery rates after IVF and
ICSI increased marginally in comparison with ﬁgures from 2006, with
minor differences in the number of embryos transferred per cycle
and rates of multiple birth.
Supplementary data
Supplementary data are available at http://humrep.oxfordjournals.
org/.
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Appendix
Contact persons representing
data collection programmes in
participating European
countries, 2007
Albania
Prof. Orion Glozheni, University Hospital for Obst & Gynecology,
Obsterics & Gynecology. Bul. B. Curri, Tirana, Albania. Tel:
+355-4-235-870; Fax: +355-4-257-688; E-mail: gliorion@icc-al.org.
Austria
Prof. Dr Heinz Strohmer, Kinderwunschzentrum Private Hospital
Goldenes Kreuz, Lazarettg, 16-18, 1090 Wien, Austria. Tel:
+43-1-40111-1400; Fax: +43-1-40111-1401; E-mail: heinz.
strohmer@kinderwunschzentrum.at.
Belgium
Dr Kris Bogaerts, I-Biostat, Kapucijnenvoer 35 bus 7001, 3000 Leuven,
Belgium. Tel: +32-16-33-68-90; Fax: +32-16-33-70-15; E-mail:
Kris.Bogaerts@med.kuleuven.be.
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Prof. Stanimir Kyurkchiev, Inst. Biology & Immunology of Reproduc-
tion, Molecular Immunology, 73, Tzaritgradsko shosse, 1113 Soﬁa,
Bulgaria. Tel: +359-2-723-890; Fax: +359-2-720-925; E-mail:
kyurkch@hotmail.com.
Cyprus
Dr Michael Pelekanos, Fertility Centre Aceso, 1, Pavlou Nirvana str.,
3021 Limassol, Cyprus. Tel: +357-99645333; Email: Pelekanos@
akeso.com.
Czech Republic
Dr Karel Rezabek, Charles University Prague, Gyn/Ob
departement, Apolinarska 18, 12000 Prague, Czech Republic.
Tel: +420-271028301; Email: krezabek@vfn.cz.
Denmark
Dr Karin Erb, Fertility Clinic, Odense University Hospital, Sdr. Boule-
vard 29, 5000 Odense C, Denmark. Tel: +45-65-41-23-24; Fax:
+45-65-90-69-82; E-mail: Karin.erb@ouh.regionsyddanmark.dk
Finland
Dr Mika Gissler, Nat. Reasearch and Develop. Centre for Wa,
P.O. Box 220, 00531 Helsinki, Finland. Tel: +385-9-39672099;
Fax: +385-9-9672459; E-mail: mika.gissler@thl.ﬁ.
France
Dr Jacques de Mouzon, INSERM, 15, Rue Guilleminot, 75014
Paris, France. Tel: +33-1-5841-2268; Fax: +33-1-5841-1539;
E-mail: jdemouzon@noos.fr; jacques.demouzon@inserm.fr.
Prof. Dominique Roye `re, Agence de la Biome ´decine, 1 Av du stade
de France, 93212 Saint-Denis La Plaine Cedex, France. Tel:
+33-1-55-93-65-50; E-mail: dominique.royere@biomedecine.fr.
Germany
Dr Klaus Bu ¨hler, Center for Gynaecology, Endocrinology and Repr
Med, Ostpassage 9, 30853 Langenhagen, Germany. Tel:
+49-511-97230-40; Fax: +49-511-97230-18; Email: k.buehler@
kinderwunsch-langenhagen.de.
Greece
Prof. Dr Basil Tarlatzis, Papageorgiou Hospital, Unit of Human Repro-
duction, Periferiakis Odos, Neas Efkarpias, 56403 Thessaloniki,
Greece. Tel: +30-231-09-91508; Fax: +30-231-0991510; E-mail:
basil.tarlatzis@gmail.com.
Hungary
Prof. G. Kosztolanyi, University of Pecs, Dept. of Medical Genetics
and Child development, Jozsef A.u 7., 7623 Pecs, Hungary.
Tel: +36-7-2535977; Fax: +36-7-2535972; E-mail: gyorgy.
kosztolanyi@aok.pte.hu.
Iceland
Mr H. Bjorgvinsson, Art Medica, IVF Unit, Baejarlind 12, 201 Kopavo-
gur, Iceland. Tel: +354-515-8100; Fax: +354-515-8103; E-mail:
Hilmar@artmedica.is.
Ireland
Dr Edgar Mocanu, HARI Unit, Rotunda Hospital, Dublin 1, Ireland.
Tel: +35-31-8072-732; Fax: +35-31-8727831; E-mail: emocanu@
rcsi.ie.
Italy
Dr Guilia Scaravelli, Registro Nazionale Medicalmente Assistita,
CNESPS, Instituto Superiore de Sanita, Viale Regina Elena, 299,
00161, Roma. Tel: +39-49904319; Fax: +39-49904324; E-mail:
guilia.scaravelli@iss.it.
Latvia
Dr Maris Arajs, EGV Clinic, Dept. of IVF, Gertrudes Str. 3,
LV 1010 Riga. Tel: +371-7-27-81-83, +371-26-55-64-66;
Fax: +371-7-31-64-67; E-mail: maris_arajs@inbox.lv.
Lithuania
Dr Zivile Gudleviciene, Baltic American, IVF Laboratory, Nemencines
rd 54A, 10103 Vilnius, Lithuania. Tel: +370-52342020; E-mail:
zivile.gudleviciene@gmail.com.
Macedonia
Dr Slobodan Lazarevski, SHOG ‘Mala Bogorodica’, Londonska 19,
1000 Skopje, Macedonia. Tel: +389-2-30-73-335; Fax:
+389-2-30-73-398; E-mail: dr.lazarevski@mbogorodica.com.mk
Montenegro
Dr Tatjana Motrenko Simic, Medical Center Cetinje, Human Repro-
duction, Vuka Micunovica 4, 81310 Cetinje, Montenegro. Tel:
+382-86232690; Fax: +382-86231336; Email: motrenko@
t-comm.me.
The Netherlands
Dr Cornelis Lambalk, Free University Hospital, Reproductive Medi-
cine, de Boelaan 1117, P.O.Box 7057, 1007 MB Amsterdam, The
Netherlands. Tel: +31-20-444-00-70; Fax: +31-20-444-00-45;
E-mail: cb.lambalk@vumc.nl.
Norway
Dr Johan T. Hazekamp, IVF-klinikken Oslo AS, PB 5014 Maj., 0301
Oslo, Norway. Tel: +47-2250-8116; Fax:+47-2320-4401; E-mail:
hazekamp@ivfoslo.nhn.no.
Poland
Prof. Rafael Kurzawa, Pomeranian Medical Academy, Department
of Reproductive Medicine and Gynaecology, 2 Siedlecka Street,
72–010 Szczecin, Poland. Tel: +48-91-487-37-55; Fax: +48-
91-425-33-12; E-mail: Kurzawa@ams.edu.pl.
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Prof. Dr Carlos Calhaz – Jorge, Faculdade de Medicina de Lisboa,
Human Reproduction Unit - Dept. of Ob/Gyn – Hosp. de Santa
Maria; Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal. Tel:
+351-217-264-229; Fax: +351-217-805-621; E-mail: calhazjorgec@
gmail.com.
Russia
Dr Vladislav Korsak, International Center for Reproductive Medicine,
General Director, Liniya 11, Building 18B, Vasilievsky Island, 199034
St-Petersburg, Russia C.I.S. Tel: +7-812-328-2251; Fax: +7-
812-327-19-50; E-mail: korsak@mcrm.ru.
Serbia
Prof. Nebosja Radunovic, Institute for Obstetrics and Gynecology,
Visegradska 26, 11000 Belgrade. Tel: +38-111-36-15592; Fax:
+38-1113615603; E-mail: radunn01@gmail.com.
Slovenia
Dr Tomaz Tomazevic, University Medical Centre Ljubljana, Obstetrics
Ginecology Reproduction, Slajmerjeva 3, 61000 Ljubljana, Slovenia.
Tel: +386-1-522-60-13; Fax: +386-1-431-43-55; E-mail:
tomaz.tomazevic@guest.arnes.si.
Spain
Dr Juana Hernandez Hernandez, Hospital San Millan, Servicio de Gine-
cologia y Obstetricia, Avda. Autonoma de la Rioja 3, 26001 Logrono,
Spain. Tel: +34-94-12-73-077; Fax: +34-94-12-73-081; E-mail:
jhernandezh@telefonica.net.
Sweden
Dr Per-Olof Karlstrom, Akademiska Hospital, Dept. Of Ob/Gyn, 751
85 Uppsala, Sweden. Tel: +46-611-2838; Fax: +46-211-31611;
E-mail: per-olof.karlstrom@karolinska.se.
Switzerland
Ms Maya Weder, Administration FIVNAT, Postfach 89, 3122 Kehrsatz,
Switzerland. Tel: +41-31-819-76-02; Fax: +41-31-819-89-20; E-mail:
administration.sgrm@bluewin.ch.
Turkey
Prof.DrTimurGu ¨rgan,GurganClinic,Infertility,Cankayacaddesi,20/3,
06680 Cankaya-Ankara, Turkey. Tel: +90-312-4427404; Fax:
+90-312-4427407; E-mail: tgurgan@gurganclinic.com.tr.
Ukraine
Dr Viktor Veselovsky, Clinic of Reproductive Medicine Nadija, 28-A,
Andriivskyyuzviz str., 01025 Kyiv, Ukraine. Tel: +380-50-311-47-38;
Fax: +380-44-5327-75-99; E-mail: v.veselovskyy@ivf.com.ua.
UK
Mr Richard Baranowski, Deputy Information Manager, Human Fertil-
ization and Embryology Authority (HFEA), 21 Bloomsbury Street,
London WC1B 3HF, UK. Tel.: +44-20-7539-3329; Fax: +44-
20-7377-1871; E-mail: Richard.baranowski@hfea.gov.uk.
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